An additional advantage to the approach involves broad applicability to mediate disease regression across solid tumor types, irrespective of cancer cell genetic heterogeneity, given the required and conserved nature of many vascular targets like VEGF/VEGFRs (43). The gene discussed is VEGFA; the disease is cancer.